Watch our CEO Jensen Huang and Chris Gibson discuss the pivotal role of #AI in transforming industries, especially #biotech. Learn how computational power and innovative thinking are accelerating #drugdiscovery processes. #healthcare #supercomputers nvda.ws/3XODHC9

It has been such a pleasure to build with our friends Bayer AG - we see the energy and execution they are bringing to our new focus in precision oncology as we push together with both quality and speed. Check out this video for a bit more on our joint work.

The Recursion and NVIDIA teams worked through day and night to get this up and running so we could get to work building larger/better biological foundation models to help us decode biology… Recursion speed because every moment matters. Thank you to all the teams

Watch Imran S. Haque (@ihaque@{bsky,genomic}.social) speak over the recent results we published in Nature Genetics. At the white-board, of course!

Very cool…

“We came to London to seek the best talent in the world." Our #London office opening brought together #techbio leaders including Dan Nathan Benaich Michael Bronstein & Zavain Dar who said: "In 10 years...the term 'techbio' will be 'bio.'" recursion.com/careers

Couldn’t agree more with Jamie Dimon’s oped… whoever leads our country going forward, we need them to do it differently, and with a team of rivals… washingtonpost.com/opinions/2024/…

Huge day for Recursion and for neuroscience - so proud of our team for doing so many world firsts to achieve this and so excited to be working with the exceptional teams at Roche and Genentech to make great strides towards new neuro targets!

I am thrilled to announce that Recursion has entered into a definitive agreement to combine with Exscientia – bringing together our high throughput target biology, foundation models & supercomputing w/ Exscientia’s generative #AI drug design & #chemistry #automation.

"It's our goal to prove that this kind of approach - about whether there's a better way to do drug discovery - that ultimately it will be faster to market, less expensive, more efficient," says Recursion CEO on using AI for pharmaceutical development:

Great to talk AI for drug discovery Andrew Ross Sorkin and Squawk Box! No more impactful use of AI than improving human health. Delighted for the planned combination between Recursion and Exscientia too! Was so great to be at their Milton Park facility checking out the

#ValteriVibes

A really thoughtful piece about Recursion's journey from unlikely start-up to TechBio leader. A big thanks to Allison DeAngelis for going deep - I don't agree with everything, but appreciate the extremely hard push on what is certainly a complicated story 😀! I have the

⁦.Recursion⁩ Mt. Olympus sunrise hike lives on!

Always good to reconnect with old friends. Even better to do it climbing for a sunrise view on top of a mountain! 🌄 I feel like there’s a pretty good chance we are all going to be making moves in techbio for some time…

Today, I’m thrilled to announce a major milestone for #patients, and for the great @Recursionpharma experiment – our first Phase 2 clinical trial readout for cerebral cavernous malformation (#CCM) showing positive topline results. REC-994 met its primary endpoint of safety &

A close-up of #astrocytes - the most abundant #cell type in the human #brain - cultured & stained in our lab. #MicroscopyMonday

Congratulations. Huge!

AI visionary Yoshua Bengio - Turing Award-winner, CS professor at Université de Montréal & our scientific advisor - discussed the role of #AI in drug discovery w/ Ben Mabey & Berton Earnshaw. The takeaway: “We are on the trajectory to build the tools to do as well as human scientists or